JP2019505527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505527A5 JP2019505527A5 JP2018537750A JP2018537750A JP2019505527A5 JP 2019505527 A5 JP2019505527 A5 JP 2019505527A5 JP 2018537750 A JP2018537750 A JP 2018537750A JP 2018537750 A JP2018537750 A JP 2018537750A JP 2019505527 A5 JP2019505527 A5 JP 2019505527A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 117
- 239000000427 antigen Substances 0.000 claims 74
- 102000036639 antigens Human genes 0.000 claims 74
- 108091007433 antigens Proteins 0.000 claims 74
- 239000012634 fragment Substances 0.000 claims 74
- 238000006467 substitution reaction Methods 0.000 claims 49
- 238000007792 addition Methods 0.000 claims 47
- 238000012217 deletion Methods 0.000 claims 44
- 230000037430 deletion Effects 0.000 claims 44
- 239000000203 mixture Substances 0.000 claims 36
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 108010074864 Factor XI Proteins 0.000 claims 18
- 230000004913 activation Effects 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 230000009424 thromboembolic effect Effects 0.000 claims 12
- 206010014522 Embolism venous Diseases 0.000 claims 10
- 208000004043 venous thromboembolism Diseases 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims 5
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 5
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 208000037819 metastatic cancer Diseases 0.000 claims 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 5
- 208000010125 myocardial infarction Diseases 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102100030563 Coagulation factor XI Human genes 0.000 claims 3
- 108010071241 Factor XIIa Proteins 0.000 claims 3
- 230000023555 blood coagulation Effects 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 230000023597 hemostasis Effects 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008718 systemic inflammatory response Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021211379A JP7366988B2 (ja) | 2016-01-22 | 2021-12-24 | 抗凝固因子ｘｉ抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281842P | 2016-01-22 | 2016-01-22 | |
| US62/281,842 | 2016-01-22 | ||
| PCT/US2017/014007 WO2017127468A1 (en) | 2016-01-22 | 2017-01-19 | Anti-coagulation factor xi antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211379A Division JP7366988B2 (ja) | 2016-01-22 | 2021-12-24 | 抗凝固因子ｘｉ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505527A JP2019505527A (ja) | 2019-02-28 |
| JP2019505527A5 true JP2019505527A5 (enExample) | 2020-02-27 |
| JP7252760B2 JP7252760B2 (ja) | 2023-04-05 |
Family
ID=57963475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537750A Active JP7252760B2 (ja) | 2016-01-22 | 2017-01-19 | 抗凝固因子ｘｉ抗体 |
| JP2021211379A Active JP7366988B2 (ja) | 2016-01-22 | 2021-12-24 | 抗凝固因子ｘｉ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211379A Active JP7366988B2 (ja) | 2016-01-22 | 2021-12-24 | 抗凝固因子ｘｉ抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10053515B2 (enExample) |
| EP (1) | EP3405498A1 (enExample) |
| JP (2) | JP7252760B2 (enExample) |
| KR (1) | KR20180104036A (enExample) |
| CN (2) | CN108884169B (enExample) |
| AR (1) | AR107505A1 (enExample) |
| AU (1) | AU2017209083A1 (enExample) |
| BR (1) | BR112018014810A2 (enExample) |
| CA (1) | CA3010224A1 (enExample) |
| JO (1) | JOP20170013B1 (enExample) |
| MA (1) | MA43660A (enExample) |
| MX (2) | MX378572B (enExample) |
| RU (2) | RU2757314C2 (enExample) |
| TW (1) | TWI736575B (enExample) |
| WO (1) | WO2017127468A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| EA201892716A1 (ru) | 2016-06-14 | 2019-05-31 | Мерк Шарп И Доум Корп. | Антитела к фактору свертывания xi |
| AU2017329645A1 (en) | 2016-09-20 | 2019-04-04 | Aronora Inc. | Novel antibodies against factor XI and uses thereof |
| JP7139332B2 (ja) * | 2016-12-23 | 2022-09-20 | ノバルティス アーゲー | 第ｘｉ因子抗体および使用方法 |
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| BR112021002472A2 (pt) * | 2018-08-09 | 2021-07-27 | Shanghai Benemae Pharmaceutical Corporation | anticorpos antifator xi |
| WO2020097336A1 (en) * | 2018-11-09 | 2020-05-14 | Beth Israel Deaconess Medical Center | Cdcp1-targeted therapies |
| KR20210118853A (ko) * | 2019-01-21 | 2021-10-01 | 아로노라 인크. | 항혈전과 항염 효과를 갖는 인자 xi에 대한 신규 인간화 항체 및 그 용도 |
| US20220106398A1 (en) * | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| CN117186232B (zh) * | 2019-04-16 | 2024-07-30 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| CN110423278B (zh) | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| CN114761036B (zh) | 2019-09-23 | 2025-09-30 | 宾夕法尼亚大学董事会 | 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体 |
| JP2023531278A (ja) * | 2020-07-03 | 2023-07-21 | スチョー アルファマブ カンパニー リミテッド | 凝固第ｘｉ因子（ｆｘｉ）結合タンパク質 |
| CA3235457A1 (en) | 2021-10-22 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Factor xi a2 domain-binding antibodies and methods of use thereof |
| CN116199782A (zh) * | 2021-11-30 | 2023-06-02 | 苏州康宁杰瑞生物科技有限公司 | 预防和/或治疗血栓栓塞性疾病的方法 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| ATE113846T1 (de) | 1988-06-21 | 1994-11-15 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (ja) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | コークス乾式消火装置のバケット巻上機の吊ビーム装置 |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
| NZ521182A (en) | 2000-03-03 | 2004-11-26 | Cambridge Antibody Tech | Human antibodies against eotaxin comprising VH adn VL domains and their use |
| WO2006069036A2 (en) | 2004-12-21 | 2006-06-29 | Centocor, Inc. | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| UA115960C2 (uk) | 2003-07-15 | 2018-01-25 | Емджен, Інк., | Людські анти-ngf нейтралізуючі антитіла як селективні інгібітори метаболічних шляхів фактора росту нервової тканини (ngf) |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| KR101017301B1 (ko) * | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| HRP20120701T1 (hr) | 2005-12-08 | 2012-10-31 | Medarex, Inc. | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 |
| SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
| KR20220031126A (ko) | 2006-06-06 | 2022-03-11 | 얀센 백신스 앤드 프리벤션 비.브이. | 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| US8598321B2 (en) | 2007-03-22 | 2013-12-03 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA3187687A1 (en) | 2007-09-14 | 2009-03-19 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| TW200927761A (en) | 2007-09-26 | 2009-07-01 | U3 Pharma Ag | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| EP3002298B1 (en) | 2007-11-21 | 2019-08-28 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| DK2297207T3 (en) | 2008-06-19 | 2018-12-03 | Prothix Bv | USING ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OR TREATMENT OF THROME CREATION |
| WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| DK2350304T3 (en) | 2008-10-31 | 2017-03-13 | Janssen Biotech Inc | TOLL-LIKE RECEPTOR 3-ANTAGONISTS |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| ES2720594T3 (es) | 2008-12-18 | 2019-07-23 | Univ Oregon Health & Science | Anticuerpos anti-fXI y métodos de uso |
| CA2755133A1 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
| EP2918602A1 (en) | 2009-04-16 | 2015-09-16 | AbbVie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
| PL2426148T3 (pl) | 2009-04-27 | 2016-01-29 | Kyowa Hakko Kirin Co Ltd | Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi |
| WO2011045704A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| WO2011079004A1 (en) | 2009-12-23 | 2011-06-30 | Schering Corporation | Cell line 3m |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| CA2818548A1 (en) | 2010-11-19 | 2012-05-24 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| CN102559720B (zh) * | 2010-12-16 | 2015-05-13 | 中国科学院福建物质结构研究所 | 人源凝血因子xi催化结构域的表达、纯化及结晶 |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| EA201391449A1 (ru) | 2011-04-01 | 2014-03-31 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Антитела против пептидов цитозоля |
| DK3424953T3 (en) | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| AU2012289001B2 (en) * | 2011-07-22 | 2016-03-03 | Csl Behring Gmbh | Inhibitory anti -factor XII/XIIa monoclonal antibodies and their uses |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| HUE031089T2 (en) | 2012-04-13 | 2017-06-28 | Rottapharm Biotech Srl | Anti-ADAMTS-5 antibody, derivatives and uses |
| SG10201609322QA (en) * | 2012-05-10 | 2017-01-27 | Bayer Pharma AG | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| HK1208474A1 (en) | 2012-05-17 | 2016-03-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind egfr |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CN106661568A (zh) | 2014-03-20 | 2017-05-10 | 日本国立感染症研究所 | 对丙型肝炎病毒具有感染抑制活性的抗体 |
| KR101753553B1 (ko) | 2014-06-03 | 2017-07-03 | 엑스바이오테크, 인크. | 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법 |
| US20170240631A1 (en) | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| PL3280441T3 (pl) | 2015-04-07 | 2022-02-21 | Alector Llc | Przeciwciała przeciwko sortilinie i sposoby ich stosowania |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
-
2017
- 2017-01-19 CA CA3010224A patent/CA3010224A1/en active Pending
- 2017-01-19 KR KR1020187023721A patent/KR20180104036A/ko not_active Withdrawn
- 2017-01-19 EP EP17703278.6A patent/EP3405498A1/en active Pending
- 2017-01-19 MX MX2018008939A patent/MX378572B/es unknown
- 2017-01-19 RU RU2018129874A patent/RU2757314C2/ru active
- 2017-01-19 RU RU2021129189A patent/RU2021129189A/ru unknown
- 2017-01-19 WO PCT/US2017/014007 patent/WO2017127468A1/en not_active Ceased
- 2017-01-19 BR BR112018014810-5A patent/BR112018014810A2/pt not_active IP Right Cessation
- 2017-01-19 CN CN201780007555.0A patent/CN108884169B/zh not_active Expired - Fee Related
- 2017-01-19 TW TW106101965A patent/TWI736575B/zh not_active IP Right Cessation
- 2017-01-19 AU AU2017209083A patent/AU2017209083A1/en not_active Abandoned
- 2017-01-19 US US15/409,607 patent/US10053515B2/en active Active
- 2017-01-19 AR ARP170100143A patent/AR107505A1/es not_active Application Discontinuation
- 2017-01-19 JO JOP/2017/0013A patent/JOP20170013B1/ar active
- 2017-01-19 CN CN202210232062.XA patent/CN114539414B/zh active Active
- 2017-01-19 JP JP2018537750A patent/JP7252760B2/ja active Active
- 2017-01-19 MA MA043660A patent/MA43660A/fr unknown
-
2018
- 2018-07-20 MX MX2021000027A patent/MX2021000027A/es unknown
- 2018-08-13 US US16/101,861 patent/US10584179B2/en active Active
-
2021
- 2021-12-24 JP JP2021211379A patent/JP7366988B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505527A5 (enExample) | ||
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| CN102089430B (zh) | 针对渐进性糖化终极产物受体(rage)的抗体及其用途 | |
| JP7293122B2 (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2020062036A5 (enExample) | ||
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2019527194A5 (enExample) | ||
| JP2020516647A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2018508188A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2013519367A5 (enExample) | ||
| JP2017507131A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| JP2016094424A5 (enExample) | ||
| JP2015509960A5 (enExample) | ||
| KR102296017B1 (ko) | 혈관 질환 및 이에 따른 합병증 치료 | |
| JPWO2020059847A5 (enExample) | ||
| JP2017527544A5 (enExample) | ||
| JP2024016024A5 (enExample) |